USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ARIETIS
Address:
650 Albany St
Boston, MA
Phone:
N/A
URL:
N/A
EIN:
120524070
DUNS:
783349058
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,080,813.00 4
SBIR Phase II $5,984,771.00 2

Award List:

THERAPY AGAINST RECALCITRANT C. albicans INFECTION

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$599,243.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is to develop an effective therapy against relapsing vaginosis caused by Candida albicans. The disease occurs in 8-9% of all women, and is recalcitrant to currently available therapies . Upon adherence to a surface, C. albicans… More

2-adamantanamine Based Therapeutic for Recurrent Oropharyngeal Candidiasis

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$598,147.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this Phase I project is to evaluate 2-adamantanamine compounds as a potential therapeutic to treat recurrent oropharyngeal candidiasis (OPC) in HIV patients. 2-adamantanamine is a close structural analog of the antivirals amantadine and rimantadine,… More

Therapy Against Recalcitrant C. albicans Infection

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$2,984,771.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): One of the important unresolved problems in fungal antimicrobial chemotherapy is the ineffectiveness of existing therapeutics against cells that do no exist in a rapidly-growing, planktonic population. Upon attachment t o abiotic surface or tissue, C. albicans… More

Compounds to treat Helicobacter pylori infection

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$585,967.00
Agency:
HHS
Principal Investigator:
Kenneth Coleman – 978-729-0580
Abstract:
DESCRIPTION (provided by applicant): The goal of this project is to discover lead compounds acting specifically against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Roughly every other person carries the pathogen, and there are an estimated 1.5 million cases… More

Narrow-spectrum Agents Acting against Helicobacter pylori

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$297,456.00
Agency:
HHS
Principal Investigator:
Kenneth Coleman – 978-729-0580
Abstract:
DESCRIPTION (provided by applicant): The goal of this project is to develop a therapeutic acting specifically against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Roughly every other person carries the pathogen, and thereare an estimated 500,000 cases annually of… More

Narrow-spectrum Agents Acting against Helicobacter pylori

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$3,000,000.00
Agency:
HHS
Principal Investigator:
Kenneth Coleman – 978-729-0580
Abstract:
DESCRIPTION (provided by applicant): The goal of this project is to develop a therapeutic acting specifically against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Roughly every other person carries the pathogen, and thereare an estimated 500,000 cases annually of… More